RxDoctor Payments Data

Michaele Oostendorp, DO

Internal Medicine · Riverview, MINPI 1154329423

Payments from drug & device makers

$8,982in general payments, 2019–2025

Across 568 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Lilly USA, LLC$903
  • Astellas Pharma US Inc$675
  • Boehringer Ingelheim$447
  • Amgen$422
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$8,88299%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,982 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$193,340
Medicare patients
419
Services billed
2,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide64$81,297
JardianceEmpagliflozin65$65,902
EliquisApixaban50$63,584
OzempicSemaglutide48$58,192
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$44,017
XareltoRivaroxaban26$21,517
JanuviaSitagliptin Phosphate20$18,206
FarxigaDapagliflozin Propanediol13$16,913
TrulicityDulaglutide11$15,286
LinzessLinaclotide11$12,409
Breo ElliptaFluticasone/Vilanterol26$11,783
OxycontinOxycodone Hcl13$11,196
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen481$10,172
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$9,237
MyrbetriqMirabegron12$8,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$903$96,58375 claims
Boehringer IngelheimJardiance$447$65,90265 claims
PfizerEliquis$341$63,58450 claims
Novo NordiskOzempic$1,677$58,19248 claims
GSKTrelegy Ellipta, Breo Ellipta$392$55,79965 claims
AstraZenecaFarxiga, Breztri Aerosphere$281$26,15026 claims
Johnson & JohnsonXarelto$131$21,51726 claims
MerckJanuvia$130$18,20620 claims
AbbVieLinzess$1,305$12,40911 claims
Astellas Pharma US IncMyrbetriq$675$8,03012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Riverview

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →